| Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trial HJL Heerspink, HH Parving, DL Andress, G Bakris, R Correa-Rotter, ... The Lancet 393 (10184), 1937-1947, 2019 | 489 | 2019 |
| Gadolinium-enhanced MR Imaging and Nephrogenic Systemic Fibrosis: Retrospective Study of a Renal Replacement Therapy Cohort1 TA Collidge, PC Thomson, PB Mark, JP Traynor, AG Jardine, STW Morris, ... Radiology 245 (1), 168-175, 2007 | 358 | 2007 |
| Redefinition of uremic cardiomyopathy by contrast-enhanced cardiac magnetic resonance imaging PB Mark, N Johnston, BA Groenning, JE Foster, KG Blyth, TN Martin, ... Kidney international 69 (10), 1839-1845, 2006 | 320 | 2006 |
| Heart failure in chronic kidney disease: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference AA House, C Wanner, MJ Sarnak, IL Piña, CW McIntyre, P Komenda, ... Kidney international 95 (6), 1304-1317, 2019 | 313 | 2019 |
| Effect of empagliflozin on left ventricular volumes in patients with type 2 diabetes, or prediabetes, and heart failure with reduced ejection fraction (SUGAR-DM-HF) MMY Lee, KJM Brooksbank, K Wetherall, K Mangion, G Roditi, ... Circulation 143 (6), 516-525, 2021 | 306 | 2021 |
| Hypertension in dialysis patients: a consensus document by the European Renal and Cardiovascular Medicine (EURECA-m) working group of the European Renal Association–European … PA Sarafidis, A Persu, R Agarwal, M Burnier, P de Leeuw, CJ Ferro, ... Nephrology dialysis transplantation 32 (4), 620-640, 2017 | 272 | 2017 |
| Electrocardiographic abnormalities and uremic cardiomyopathy GA Stewart, RT Gansevoort, PB Mark, E Rooney, TA Mcdonagh, ... Kidney international 67 (1), 217-226, 2005 | 272 | 2005 |
| Contrast enhanced-cardiovascular magnetic resonance imaging in patients with pulmonary hypertension KG Blyth, BA Groenning, TN Martin, JE Foster, PB Mark, HJ Dargie, ... European heart journal 26 (19), 1993-1999, 2005 | 265 | 2005 |
| Chronic kidney disease and arrhythmias: conclusions from a kidney disease: improving global outcomes (KDIGO) controversies conference MP Turakhia, PJ Blankestijn, JJ Carrero, CM Clase, R Deo, CA Herzog, ... European heart journal 39 (24), 2314-2325, 2018 | 260 | 2018 |
| Cardiovascular morbidity and mortality after kidney transplantation S Stoumpos, AG Jardine, PB Mark Transplant International 28 (1), 10-21, 2015 | 255 | 2015 |
| Glomerular filtration rate by differing measures, albuminuria and prediction of cardiovascular disease, mortality and end-stage kidney disease JS Lees, CE Welsh, CA Celis-Morales, D Mackay, J Lewsey, SR Gray, ... Nature medicine 25 (11), 1753-1760, 2019 | 217 | 2019 |
| Renal association clinical practice guideline in post-operative care in the kidney transplant recipient RJ Baker, PB Mark, RK Patel, KK Stevens, N Palmer BMC nephrology 18, 1-41, 2017 | 207 | 2017 |
| Impact of renal function on the effects of LDL cholesterol lowering with statin-based regimens: a meta-analysis of individual participant data from 28 randomised trials W Herrington, J Emberson, B Mihaylova, L Blackwell, C Reith, R Haynes, ... Lancet Diabetes and Endocrinology 4 (10), 2016 | 200 | 2016 |
| Lipid management in patients with chronic kidney disease CJ Ferro, PB Mark, M Kanbay, P Sarafidis, GH Heine, P Rossignol, ... Nature Reviews Nephrology 14 (12), 727-749, 2018 | 199 | 2018 |
| NT-proBNP can be used to detect right ventricular systolic dysfunction in pulmonary hypertension KG Blyth, BA Groenning, PB Mark, TN Martin, JE Foster, T Steedman, ... European Respiratory Journal 29 (4), 737-744, 2007 | 185 | 2007 |
| Effect of mineralocorticoid receptor antagonists on proteinuria and progression of chronic kidney disease: a systematic review and meta-analysis G Currie, AHM Taylor, T Fujita, H Ohtsu, M Lindhardt, P Rossing, ... BMC nephrology 17, 1-14, 2016 | 171 | 2016 |
| Intravenous ferric derisomaltose in patients with heart failure and iron deficiency in the UK (IRONMAN): an investigator-initiated, prospective, randomised, open-label, blinded … PR Kalra, JGF Cleland, MC Petrie, EA Thomson, PA Kalra, IB Squire, ... The Lancet 400 (10369), 2199-2209, 2022 | 167 | 2022 |
| The dapagliflozin and prevention of adverse outcomes in chronic kidney disease (DAPA-CKD) trial: baseline characteristics DC Wheeler, BV Stefansson, M Batiushin, O Bilchenko, DZI Cherney, ... Nephrology Dialysis Transplantation 35 (10), 1700-1711, 2020 | 160 | 2020 |
| Blood pressure changes after renal denervation at 10 European expert centers A Persu, Y Jin, M Azizi, M Baelen, S Völz, A Elvan, F Severino, J Rosa, ... Journal of human hypertension 28 (3), 150-156, 2014 | 159 | 2014 |
| Investigating the relationship between cerebral blood flow and cognitive function in hemodialysis patients MD Findlay, J Dawson, DA Dickie, KP Forbes, D McGlynn, T Quinn, ... Journal of the American Society of Nephrology 30 (1), 147-158, 2019 | 155 | 2019 |
Jennifer S LeesClinical Research Fellow, University of GlasgowVerified email at glasgow.ac.uk
